Prime Medicine's program leverages the Company's universal liver lipid nanoparticle (LNP) to edit the E342K (Pi*Z) mutation in the SERPINA1 gene, the prevalent disease-causing mutation in AATD, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback